CytoDyn to present poster at AACR conference on mTNBC

CytoDyn (CYDY) will present a poster and an oral presentation at the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, taking place September 24, to September 27, 2025, in Montreal, Canada. Key Findings: CCR5 inhibition combined with ICI therapy increased overall survival in patients with metastatic triple-negative breast cancer, mTNBC, with 18% of heavily pretreated mTNBC patients alive after a median of ~60 months. Inhibition of CCR5 by leronlimab induced PD-L1 expression on patient circulating tumor cells. Expression levels of CCR5 correlate with T cell infiltration in TNBC. “These impressive findings on how leronlimab can serve to make metastatic triple-negative breast cancer cells more responsive to checkpoint inhibitors are of great value as we move this asset forward for oncology indications,” said Jacob Lalezari, M.D., CEO of CytoDyn. “Understanding this immune-modulating mechanism not only deepens insight into how leronlimab works, but also supports its potential as a broadly applicable therapy for a range of solid tumors that historically have had limited treatment options.”